Barbara Colombi

Barbara Colombi

Auto-generated profile, based on publicly available information

Barbara Colombi

Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
SPSilvia G. Priori
Silvia G. Priori
CNCarlo Napolitano
Carlo Napolitano
MMMirella Memmi
Mirella Memmi
BCBarbara Colombi
Barbara Colombi
FDFabrizio Drago
Fabrizio Drago
ADAngelica DeLogu
Angelica DeLogu
Background — Mutations in the cardiac ryanodine receptor gene ( RyR2 ) underlie catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited arrhythmogenic disease occurring in the structurally intact heart. The proportion of patients with CPVT carrying RyR2 mutations is unknown, and the clinical features of RyR2 -CPVT as compared with nongenotyped CPVT are undefined. Methods and Results — Patients with documented polymorphic ventricular arrhythmias occurring during physical or emotional stress with a normal heart entered the study. The clinical phenotype of the 30 probands and of 118 family members was evaluated, and mutation screening on the RyR2 gene was performed. Arrhythmias documented in probands were: 14 of 30 bidirectional ventricular tachycardia, 12 of 30 polymorphic ventricular tachycardia, and 4 of 30 catecholaminergic idiopathic ventricular fibrillation; RyR2 mutations were identified in 14 of 30 probands (36% bidirectional ventricular tachycardia, 58% polymorphic ventricular tachycardia, 50% catecholaminergic idiopathic ventricular fibrillation) and in 9 family members (4 silent gene carriers). Genotype-phenotype analysis showed that patients with RyR2 CPVT have events at a younger age than do patients with nongenotyped CPVT and that male sex is a risk factor for syncope in RyR2 -CPVT (relative risk=4.2). Conclusions — CPVT is a clinically and genetically heterogeneous disease manifesting beyond pediatric age with a spectrum of polymorphic arrhythmias. β-Blockers reduce arrhythmias, but in 30% of patients an implantable defibrillator may be required. Genetic analysis identifies two groups of patients: Patients with nongenotyped CPVT are predominantly women and become symptomatic later in life; patients with RyR2 CPVT become symptomatic earlier, and men are at higher risk of cardiac events. These data provide a rationale for prompt evaluation and treatment of young men with RyR2 mutations.

4 August 2006 in Circulation Research
Verified
Journal Article
Closed access
NLNian Liu
Nian Liu
BCBarbara Colombi
Barbara Colombi
MMMirella Memmi
Mirella Memmi
SZSpyros Zissimopoulos
Spyros Zissimopoulos
NRNicoletta Rizzi
Nicoletta Rizzi
SPSilvia G. Priori
Silvia G. Priori
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by life threatening arrhythmias and mutations in the gene encoding the ryanodine receptor (RyR2). Disagreement exists on whether (1) RyR2 mutations induce abnormal calcium transients in the absence of adrenergic stimulation; (2) decreased affinity of mutant RyR2 for FKBP12.6 causes CPVT; (3) K201 prevent arrhythmias by normalizing the FKBP12.6-RyR2 binding. We studied ventricular myocytes isolated from wild-type (WT) and knock-in mice harboring the R4496C mutation (RyR2 R4496C+/− ). Pacing protocols did not elicit delayed afterdepolarizations (DADs) (n=20) in WT but induced DADs in 21 of 33 (63%) RyR2 R4496C+/− myocytes ( P =0.001). Superfusion with isoproterenol (30 nmol/L) induced small DADs (45%) and no triggered activity in WT myocytes, whereas it elicited DADs in 87% and triggered activity in 60% of RyR2 R4496C+/− myocytes ( P =0.001). DADs and triggered activity were abolished by ryanodine (10 μmol/L) but not by K201 (1 μmol/L or 10 μmol/L). In vivo administration of K201 failed to prevent induction of polymorphic ventricular tachycardia (VT) in RyR2 R4496C+/− mice. Measurement of the FKBP12.6/RyR2 ratio in the heavy sarcoplasmic reticulum membrane showed normal RyR2–FKBP12.6 interaction both in WT and RyR2 R4496C+/− either before and after treatment with caffeine and epinephrine. We suggest that (1) triggered activity is the likely arrhythmogenic mechanism of CPVT; (2) K201 fails to prevent DADs in RyR2 R4496C+/− myocytes and ventricular arrhythmias in RyR2 R4496C+/− mice; and (3) RyR2–FKBP12.6 interaction in RyR2 R4496C+/− is identical to that of WT both before and after epinephrine and caffeine, thus suggesting that it is unlikely that the R4496C mutation interferes with the RyR2/FKBP12.6 complex.

27 May 2005 in Circulation Research
Verified
Journal Article
Closed access
MCMarina Cerrone
Marina Cerrone
BCBarbara Colombi
Barbara Colombi
Massimo SantoroMassimo Santoro
Massimo Santoro
MBMarina Raffaele di Barletta
Marina Raffaele di Barletta
MSMario Scelsi
Mario Scelsi
SPSilvia G Priori
Silvia G Priori
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by adrenergically mediated polymorphic ventricular tachycardia leading to syncope and sudden cardiac death. The autosomal dominant form of CPVT is caused by mutations in the RyR2 gene encoding the cardiac isoform of the ryanodine receptor. In vitro functional characterization of mutant RyR2 channels showed altered behavior on adrenergic stimulation and caffeine administration with enhanced calcium release from the sarcoplasmic reticulum. As of today no experimental evidence is available to demonstrate that RyR2 mutations can reproduce the arrhythmias observed in CPVT patients. We developed a conditional knock-in mouse model carrier of the R4496C mutation, the mouse equivalent to the R4497C mutations identified in CPVT families, to evaluate if the animals would develop a CPVT phenotype and if beta blockers would prevent arrhythmias. Twenty-six mice (12 wild-type (WT) and 14RyR R4496C ) underwent exercise stress testing followed by epinephrine administration: none of the WT developed ventricular tachycardia (VT) versus 5/14 RyR R4496C mice ( P =0.02). Twenty-one mice (8 WT, 8 RyR R4496C , and 5 RyR R4496C pretreated with beta-blockers) received epinephrine and caffeine: 4/8 (50%) RyR R4496C mice but none of the WT developed VT ( P =0.02); 4/5 RyR R4496C mice pretreated with propranolol developed VT ( P =0.56 nonsignificant versus RyR R4496C mice). These data provide the first experimental demonstration that the R4496C RyR2 mutation predisposes the murine heart to VT and VF in response caffeine and/or adrenergic stimulation. Furthermore, the results show that analogous to what is observed in patients, beta adrenergic stimulation seems ineffective in preventing life-threatening arrhythmias.

30 January 2009 in Circulation Research
Verified
Journal Article
Closed access
PDF file
MFMaría FernánDez-Velasco
María FernánDez-Velasco
Angélica RuedaAngélica Rueda
Angélica Rueda
NRNicoletta Rizzi
Nicoletta Rizzi
Jean-Pierre BenitahJean-Pierre Benitah
Jean-Pierre Benitah
BCBarbara Colombi
Barbara Colombi
Ana M. GómezAna M. Gómez
Ana M. Gómez
Cardiac ryanodine receptor (RyR2) mutations are associated with autosomal dominant catecholaminergic polymorphic ventricular tachycardia, suggesting that alterations in Ca 2+ handling underlie this disease. Here we analyze the underlying Ca 2+ release defect that leads to arrhythmia in cardiomyocytes isolated from heterozygous knock-in mice carrying the RyR2 R4496C mutation. RyR2 R4496C−/− littermates (wild type) were used as controls. [Ca 2+ ] i transients were obtained by field stimulation in fluo-3–loaded cardiomyocytes and viewed using confocal microscopy. In our basal recording conditions (2-Hz stimulation rate), [Ca 2+ ] i transients and sarcoplasmic reticulum Ca 2+ load were similar in wild-type and RyR2 R4496C cells. However, paced RyR2 R4496C ventricular myocytes presented abnormal Ca 2+ release during the diastolic period, viewed as Ca 2+ waves, consistent with the occurrence of delayed afterdepolarizations. The occurrence of this abnormal Ca 2+ release was enhanced at faster stimulation rates and by β-adrenergic stimulation, which also induced triggered activity. Spontaneous Ca 2+ sparks were more frequent in RyR2 R4496C myocytes, indicating increased RyR2 R4496C activity. When permeabilized cells were exposed to different cytosolic [Ca 2+ ] i , RyR2 R4496C showed a dramatic increase in Ca 2+ sensitivity. Isoproterenol increased [Ca 2+ ] i transient amplitude and Ca 2+ spark frequency to the same extent in wild-type and RyR2 R4496C cells, indicating that the β-adrenergic sensitivity of RyR2 R4496C cells remained unaltered. This effect was independent of protein expression variations because no difference was found in the total or phosphorylated RyR2 expression levels. In conclusion, the arrhythmogenic potential of the RyR2 R4496C mutation is attributable to the increased Ca 2+ sensitivity of RyR2 R4496C , which induces diastolic Ca 2+ release and lowers the threshold for triggered activity.

1 August 2008 in Circulation Research
Verified
Journal Article
Closed access
NRNicoletta Rizzi
Nicoletta Rizzi
NLNian Liu
Nian Liu
CNCarlo Napolitano
Carlo Napolitano
ANAlessandra Nori
Alessandra Nori
FTFederica Turcato
Federica Turcato
SPSilvia G. Priori
Silvia G. Priori
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disorder characterized by life threatening arrhythmias elicited by physical and emotional stress in young individuals. The recessive form of CPVT is associated with mutation in the cardiac calsequestrin gene ( CASQ2 ). We engineered and characterized a homozygous CASQ2 R33Q/R33Q mouse model that closely mimics the clinical phenotype of CPVT patients. CASQ2 R33Q/R33Q mice develop bidirectional VT on exposure to environmental stress whereas CASQ2 R33Q/R33Q myocytes show reduction of the sarcoplasmic reticulum (SR) calcium content, adrenergically mediated delayed (DADs) and early (EADs) afterdepolarizations leading to triggered activity. Furthermore triadin, junctin, and CASQ2-R33Q proteins are significantly decreased in knock-in mice despite normal levels of mRNA, whereas the ryanodine receptor (RyR2), calreticulin, phospholamban, and SERCA2a-ATPase are not changed. Trypsin digestion studies show increased susceptibility to proteolysis of mutant CASQ2. Despite normal histology, CASQ2 R33Q/R33Q hearts display ultrastructural changes such as disarray of junctional electron-dense material, referable to CASQ2 polymers, dilatation of junctional SR, yet normal total SR volume. Based on the foregoings, we propose that the phenotype of the CASQ2 R33Q/R33Q CPVT mouse model is portrayed by an unexpected set of abnormalities including (1) reduced CASQ2 content, possibly attributable to increased degradation of CASQ2-R33Q, (2) reduction of SR calcium content, (3) dilatation of junctional SR, and (4) impaired clustering of mutant CASQ2.

1 January 2011 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
NLNian Liu
Nian Liu
YRYanfei Ruan
Yanfei Ruan
MDMarco Denegri
Marco Denegri
TBTiziana Bachetti
Tiziana Bachetti
YLYang Li
Yang Li
SPSilvia G. Priori
Silvia G. Priori